Test: Castle Creek Pharmaceuticals Receives Partners in Progress Award from debra of America
Company recognized for clinical research in epidermolysis bullosa simplex at the 19th Annual debra of America Benefit
PARSIPPANY, NJ – October 27, 2017 – Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions, today announced that the company received the Partners in Progress Award at the 19th Annual debra of America (Dystrophic Epidermolysis Bullosa Research Association of America) Benefit held October 26, 2017 at Guastavino’s in New York City.
The award recognizes the company’s progress in developing an investigational topical diacerein 1% ointment (CCP-020) that is being evaluated for the treatment of epidermolysis bullosa simplex (EBS), a rare genetic condition that leads to extremely fragile skin resulting in mild to severe blistering, skin erosion and peeling of the epidermis layers in response to minor injury or friction.
“We are honored to be recognized by debra of America as we continue our efforts to develop a potentially disease-modifying therapy for people living with EBS, the most common form of epidermolysis bullosa,” said Michael Derby, co-founder and chief executive officer at Castle Creek Pharmaceuticals. “Currently there are no treatment options that target the underlying cause of EBS, and we are focused on delivering new options to patients around the world who are fighting this debilitating condition.”
CCP-020 is engineered to block an important inflammatory signaling pathway associated with EBS, which could strengthen epidermal tissue and support healing. In a previously completed Phase 2 clinical trial that included 17 patients with EBS, 60 percent of patients treated with CCP-020 experienced at least a 40 percent reduction in blistering after four weeks.
The first patient was enrolled in the company’s Phase 2/3 DELIVERS study in June 2017, which is evaluating the safety and efficacy of CCP-020 for the treatment of EBS. For more information about the DELIVERS study, visit www.deliversebs.com.
About Castle Creek Pharmaceuticals
Castle Creek Pharmaceuticals (CCP), a member of the Paragon Biosciences corporate family, is a privately held biopharmaceutical company with a robust and diversified pipeline of late-stage products. The company business strategy is based on a demonstrated ability to identify and advance therapies backed by strong science with the potential to represent significant advances in the treatment of debilitating dermatologic and head and neck conditions with high unmet needs. For more information, please visit www.castlecreekpharma.com.